Premier Alternatives

Elegen

Menlo Park, CA · Founded 2017 · Privately Held (backing)

Developer of microfluidics technology designed to disrupt synthetic biology. Elegen is based in Menlo Park, CA and was founded in 2017. Its last known valuation is $100 million. It has raised $56.6 million across 1 recorded round; the latest was a $33 million early-stage round in May 2024.

Last price · $/share
—
Implied valuation
$100.0M
Total raised
$56.6M
Last round
Early Stage VC
May 2024

Elegen key facts

  • Developer of microfluidics technology designed to disrupt synthetic biology.
  • Elegen’s last known valuation is $100.0M.
  • It has raised $56.6M across 1 recorded rounds; the latest was Early Stage VC ($33.0M) in May 2024.
  • Notable investors include Y Combinator, Andreessen Horowitz, 8VC, National Institutes of Health, In-Q-Tel — 17 tracked in total.
  • Elegen has filed 1 Form D with the SEC, most recently May 2024 ($33.0M sold to 28 investors).
  • Status: Privately Held (backing).
Free account
More of Elegen with a free account
  • ·The complete investor list: 17 names
  • ·Watch Elegen: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Elegen funding rounds

1 rounds
May 2024Early Stage VC$33.0MSEC filing▮
Full funding history →

Elegen valuation

Elegen's last known valuation is $100 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How much has Elegen raised?

Elegen has raised $56.6 million in total; 1 of its rounds is on record. The largest on record was a $33 million early-stage round in May 2024.

Elegen has filed 1 Form D with the SEC, most recently in May 2024 ($33 million sold to 28 investors).

Elegen investors

17 investors are on record for Elegen, including Y Combinator, Andreessen Horowitz, 8VC and National Institutes of Health. By type, the record holds 7 venture capital firms and 1 asset manager. The early-stage round in May 2024 drew 28 investors.

About Elegen

Developer of microfluidics technology designed to disrupt synthetic biology. The company leverages technology for the engineering of entire genomes and the rapid development of DNA synthesizers aimed at accelerating biomedical advances, enabling clients to facilitate DNA sequence testing.

Sector
Healthcare
HQ
Menlo Park, CA, United States
Founded
2017
Employees
96
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$100.0M

Elegen’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.